126 related articles for article (PubMed ID: 9364245)
1. Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.
Legovini P; De Menis E; Breda F; Billeci D; Carteri A; Pavan P; Conte N
J Endocrinol Invest; 1997 Sep; 20(8):434-8. PubMed ID: 9364245
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of acromegaly with lanreotide: evidence of increased serum parathormone concentration.
Cappelli C; Gandossi E; Agosti B; Cerudelli B; Cumetti D; Castellano M; Pirola I; De Martino E; Rosei EA
Endocr J; 2004 Dec; 51(6):517-20. PubMed ID: 15644568
[TBL] [Abstract][Full Text] [Related]
3. Biochemical assessment of bone formation and resorption in acromegaly.
Ezzat S; Melmed S; Endres D; Eyre DR; Singer FR
J Clin Endocrinol Metab; 1993 Jun; 76(6):1452-7. PubMed ID: 8501150
[TBL] [Abstract][Full Text] [Related]
4. The short and long-term effects of octreotide on calcium homeostasis in patients with acromegaly.
Fredstorp L; Pernow Y; Werner S
Clin Endocrinol (Oxf); 1993 Sep; 39(3):331-6. PubMed ID: 8222295
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.
Terzolo M; Piovesan A; Osella G; Pia A; Reimondo G; Pozzi C; Raucci C; Torta M; Paccotti P; Angeli A
Calcif Tissue Int; 1993 Mar; 52(3):188-91. PubMed ID: 8481830
[TBL] [Abstract][Full Text] [Related]
6. Gonadal status is an important determinant of bone density in acromegaly.
Lesse GP; Fraser WD; Farquharson R; Hipkin L; Vora JP
Clin Endocrinol (Oxf); 1998 Jan; 48(1):59-65. PubMed ID: 9509069
[TBL] [Abstract][Full Text] [Related]
7. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
8. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
9. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Eur J Endocrinol; 2005 Jan; 152(1):53-60. PubMed ID: 15762187
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
Fredstorp L; Werner S
J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
[TBL] [Abstract][Full Text] [Related]
11. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
Plöckinger U; Liehr RM; Quabbe HJ
J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome.
Piovesan A; Terzolo M; Reimondo G; Pia A; Codegone A; Osella G; Boccuzzi A; Paccotti P; Angeli A
Horm Metab Res; 1994 May; 26(5):234-7. PubMed ID: 8076906
[TBL] [Abstract][Full Text] [Related]
13. Serum bone Gla protein as a marker of bone turnover in acromegaly.
Marazuela M; Astigarraga B; Tabuenca MJ; Estrada J; Marín F; Lucas T
Calcif Tissue Int; 1993 Jun; 52(6):419-21. PubMed ID: 8369987
[TBL] [Abstract][Full Text] [Related]
14. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
15. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study.
Hansen TB; Brixen K; Vahl N; Jørgensen JO; Christiansen JS; Mosekilde L; Hagen C
J Clin Endocrinol Metab; 1996 Sep; 81(9):3352-9. PubMed ID: 8784096
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
[TBL] [Abstract][Full Text] [Related]
17. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
[TBL] [Abstract][Full Text] [Related]
19. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
